Phaseline

Targets › MENIN

MENIN: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Mar 2027.

Open in Phaseline: the race on MENIN, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
The First Affiliated Hospital of Soochow UniversityBY002
Menin inhibitor targeting KMT2A-rearranged and NPM1-mutant acute leukemia
KMT2A, MENINPhase 1Acute LeukemiaMar 2027

Conditions

Acute Leukemia (1)

Modalities

small molecule (1)

Companies

The First Affiliated Hospital of Soochow University (1)

Related targets

KMT2A (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.